|
|
 |
|
Viewing report
|
|
|
|
Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi
Business Insights, April 2005, Pages: 186
Emerging Drug Discovery Technologies
Executive Summary
Introduction
Lab-on-a-chip/microfluidics
Nanotechnology
RNA interference
Chapter 1 Introduction
Summary
Overview
A historical overview of the drug discovery process
Drug discovery in the 1950s and 1960s
Drug discovery in the 1980s
Drug discovery today
Emerging drug discovery technologies
Lab-on-a-chip/microfluidic technologies
Nanotechnology
RNA interference
Report objectives
Chapter 2 Lab-on-a-chip/microfluidics
Summary
Introduction
LOC technologies
LOC design issues
Microarrays
Spotted microarrays
In situ fabricated arrays
DNA applications
Protein applications
The LabChip
Lab-on-a-CD
Chip-based electrospray system for mass spectroscopy
HPLC-on-a-chip
Microfluidic PCR
Multiplexed capillary electrophoresis
Market drivers and restraints
Market drivers
HTS
Reduction of human error
Reduced exposure to hazardous materials
Reduction in sample requirement and routine tasks
Cost savings
Market restraints
Reduction in demand
Reluctance to replace old systems with new technologies
Market analysis
Competitive structure
Market share
Aclara BioSciences
Advion BioSciences, Inc.
Agilent Technologies
BioMicro Systems
BioTrove Inc.
Caliper Life Sciences
Cepheid
CombiMatrix Corp.
Eksigent Technologies
Epigem Limited
Fluidigm Corp.
Gyros AB
Nanogen
Nanostream Inc.
Protiveris
Sequenom
Zyomyx
Future developments
Chapter 3 Nanotechnology
Summary
Introduction
Nanotechnologies
Applications
Drug discovery and drug delivery
Biosensing
Other applications
Public opinion
Funding
Market
Nano-enabled drug discovery tools
Atomic force microscopy
Nano-mass spectroscopy
Dip-pen nanolithography
Nanoarrays
Nanoparticles for drug discovery
Quantum dots and gold nanoparticles
Nanoshells
Nanobarcode particles
Nano-enabled drugs
Abraxane
RenaZorb
Antimicrobial emulsions
Antioxidants and fullerenes
Industry challenges 1
High demands of drug discovery applications
Long-term stability of nanomaterials
Technical issues in nano-assembly and molecular manufacturing
Barriers to collaborations
Lack of test standardization
Scalability
Pharmaceutical companies reluctant to invest in nanotechnology
Funding for nanotechnology
Market drivers and restraints
Market drivers
Technological drivers
Increased funding
Social and economic factors
Market restraints
Uncertainty
Public awareness
Environmental concerns
Detection of incurable diseases
Large expectations
Market analysis
Competitive structure
Market share
3DM Inc.
Alnis Biosciences Inc.
American Pharmaceuticals Partners Inc.
BioCrystal Ltd.
BioForce NanoSciences Inc.
CrystalPlex Corp.
C Sixty Inc.
Evident Technologies, Inc.
NanBio Corp.
Nanosphere
PharmaSeq, Inc
Quantum Dot Corp.
Future developments
Chapter 4 RNA interference (RNAi)
Summary
Introduction
Gene silencing
Methods for gene silencing
Aptamers
Ribozymes
Peptide nucleic acid (PNA) and PNA-DNA chimeras
Antisense oligonucleotides
RNA interference (RNAi)
RNAi mechanism
RNAi approaches
siRNA
ddRNAi
MicroRNAs (miRNAs)
Short hairpin RNAs (shRNAs)
Delivery methods
Delivery using chemical transfections
Delivery using electroporation
Delivery using expression vectors
Delivery using cell-penetrating peptides
In vivo delivery of siRNAs
Industry challenges
Intellectual property issues
Off-target effects
Delivery of siRNA in vitro and in vivo
Toxicity issues from RNAi
Pricing issues
Efficacy of RNAi
Standardization of technologies
Proof of therapeutic potential
Market drivers and restraints
Market drivers
Demand for accelerated drug discovery
Resolution of intellectual property issues
Robust, efficient and potent technology
Functional genomics and proteomics studies
Vector-based and siRNA price decline
Reliability
Market restraints
Expensive RNAi reagents
Delivery of siRNA
Failure of antisense drugs
Lack of robust clinical data
Selection and design of appropriate siRNA
Toxicity and off-target effects
Market analysis
Revenue forecasts
Trends by geographic region
North America
Europe
Japan
Rest of the World
Competitive structure
Market share analysis
Ambion
Alnylam Pharmaceuticals, Inc.
Benitec Ltd
CytRx Corp.
Cenix BioScience
Devgen
Dharmacon, Inc.
Eurogentec (EGT)
Imgenex Corp.
Immusol Inc.
Invitrogen Corp.
InvivoGen
MWG Biotech
Proligo
Promega
Qiagen.
Sirna Therapeutics
Future developments
Chapter 5 Appendix
Research methodology and information sources
Primary research methodology
Secondary research methodology
Market sizing
Forecasting
Index
Abbreviations and acronyms
List of Figures
Figure 1.1: Drug development process during the 1950s and 1960s
Figure 1.2: Drug development process during the 1980s
Figure 1.3: Drug development process today
Figure 2.1: The Gyros Bioaffy lab-on-a-CD
Figure 2.2: Advion BioSciences' ESI Chip
Figure 2.3: HPLC-on-a-chip
Figure 2.4: Cepheid's GeneXpert cartridges for PCR analysis
Figure 2.5: Market drivers and restraints for LOC/microfluidics devices in drug discovery
Figure 2.6: Microfluidics/LOC revenue forecasts, 2005-2012
Figure 2.7: Microfluidics/lab-on-a-chip market shares, 2004
Figure 3.1: Expression of cells using QDots
Figure 3.2: Binding of Nanosphere's nanoparticle probe to a selected genetic or proteomic target
Figure 3.3: Nano-enabled drug discovery industry challenges
Figure 3.4: Market drivers and restraints for nano-enabled drug discovery
Figure 3.5: Nano-enabled drug discovery revenue forecasts, 2004-2012
Figure 3.6: Nanoenabled drug discovery market shares, 2004
Figure 4.7: RNAi pathways
Figure 4.8: Industry challenges faced by RNAi industry participants
Figure 4.9: Market drivers and restraints for RNAi technology
Figure 4.10: RNAi revenue forecasts and growth rates, 2004-2012
Figure 4.11: RNAi revenues by geographic region, 2004
Figure 4.12 RNAi market shares, 2004
List of Tables
Table 2.1: Microfluidics/LOC revenue forecasts, 2005-2012
Table 3.2: Nano-enabled drug discovery revenue forecasts, 2004-2012
Table 4.3: RNAi revenue forecasts, 2004-2012
Table 5.4: Abbreviations and acronyms, A-L
Table 5.5: Abbreviations and acronyms, M-Z
Customers who bought this item also bought
RNAi - Technologies, Markets and Companies
RNAi 2008
Advances in Lab-on-Chip and Microfluidics Technologies for Drug Discovery and Clinical Diagnostics
The Outlook For RNAi: Accelerating Drug Discovery and the Development of RNAi Therapeutics
Outlook for RNAi, 2007: siRNA and miRNA in Biology, Diagnostics and Therapeutics
Lab on a Chip (LOC) -- Advances in Microfluidics
The Future of RNAi Therapeutics: Drug Pipelines and Prospects
Realizing the Promise of Therapeutic RNAi: Emerging Strategies for RNAi Delivery
RNA Interference for Drug R&D: Applications, Alliances, Companies and WW Market to 2011
The Role of Nanotechnology in European Drug Discovery
RNAi Therapeutics 2008 Market Report
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
|
|
|
|
